focus -WSS

focus

author：explore 2025-10-01 06:01:03 - browse：42

A man enters the Regeneron Clinic at a monoclonal antibody treatment site in Pembroke Pines, Florida – politics and policy coverage from STAT — Regeneron agreed to price limits for a new Covid-19 drug that will be developed in partnership with the Department of Health and Human Services. CHANDAN KHANNA/AFP via Getty Images

WASHINGTON — A groundbreaking clause in a new deal between the Department of Health and Human Services and the pharmaceutical company Regeneron marks the first time the Biden administration has directly used its leverage to challenge drugmakers’ list prices, experts told STAT.

The contract between Regeneron and the government requires that the list price for a future monoclonal antibody drug to prevent Covid-19 is the same or lower in the United States as in other high-income countries. The release doesn’t explain which countries the government will be comparing prices with, or how pricing data will be determined.

The deal was part of the White House’s Project NextGen initiative, which includes $5 billion in new vaccines and therapies. HHS announced that it is spending $326 million to help Regeneron develop a new monoclonal antibody to prevent Covid-19. Regeneron in January announced plans to start testing a potentially variant-proof antibody, which is set to go into clinical trials later this year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Merck drug for rare lung condition set for approval in U.S.

WSS

Why you get paid to donate plasma but not blood

Abortion pill case raises question: who can sue the FDA?

Patient advocates debate FDA's accelerated approval process

Merck drug for rare lung condition set for approval in U.S.

There's no autism epidemic. It's an autism diagnosis epidemic

Phoenix breaks record with 19 consecutive days above 110 degrees Fahrenheit

knowledge

focus

focus

Hepatitis C has a cure — but many Americans still lack access to it

Readout LOUD podcast: mifepristone case, GLP

Novavax promises a turnaround & Lilly roils the obesity market

Merck drug for rare lung condition set for approval in U.S.

BioMarin wins approval for gene therapy to treat hemophilia A

Why the world’s most expensive drug might be worth the price

After affirmative action ruling, medical educators look to 'holistic review'

Johnson & Johnson sues to stop Medicare negotiation

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Steward Health Care has deal to sell doctor network to UnitedHealth

leisure time

Manchin plays down potential 3rd

Steward Health Care has deal to sell doctor network to UnitedHealth

Readout Newsletter: WuXi and Congress, Boundless Bio, etc.

Study: Hearing aids may slow cognitive decline in those at risk

Washington mulls new rules to avert another Change Healthcare

FDA's naming rule on biosimilars has undermined competition

leisure time

focus

explore

Wikipedia